Eli Lilly and Company (LLY)vsRapport Therapeutics, Inc. Common Stock (RAPP)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
RAPP
Rapport Therapeutics, Inc. Common Stock
$43.62
+0.37%
HEALTHCARE · Cap: $2.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 398230% more annual revenue ($79.67B vs $20.00M). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
RAPP
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : RAPP
The strongest argument for RAPP centers on Debt/Equity, Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : RAPP
The primary concerns for RAPP are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while RAPP is a value play — different risk/reward profiles.
RAPP carries more volatility with a beta of 1.03 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 24/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Rapport Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated cognitive disorders. Utilizing proprietary drug candidates and cutting-edge technology platforms, the firm is focused on meeting significant unmet medical needs through comprehensive scientific research and clinical trials. With a robust pipeline of innovative treatment options, Rapport Therapeutics is strategically poised to reshape the treatment paradigm for individuals facing the challenges of cognitive impairments, enhancing patient quality of life and contributing to the broader healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?